🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

George Soros’s ESPR Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+757,358 Shares
Current Position
757,358 Shares
$2.39 M Value

George Soros's ESPR Position Overview

George Soros (via Soros Fund Management LLC) currently holds 757,358 shares of Esperion Therapeutics, Inc. (ESPR) worth $2.39 M, representing 0.03% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, George Soros has initiated a new position in ESPR, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

George Soros's Esperion Therapeutics (ESPR) Holding Value Over Time

Track share changes against reported price movement

Quarterly Esperion Therapeutics (ESPR) Trades by George Soros

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +757,358 New Buy 757,358 $3.16

George Soros's Esperion Therapeutics Investment FAQs

George Soros first purchased Esperion Therapeutics, Inc. (ESPR) in Q2 2026, acquiring 757,358 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

George Soros has held Esperion Therapeutics, Inc. (ESPR) for 1 quarters since Q2 2026.

George Soros's largest addition to Esperion Therapeutics, Inc. (ESPR) was in Q2 2026, adding 757,358 shares worth $2.39 M.

According to the latest 13F filing for Q2 2026, George Soros's firm, Soros Fund Management LLC, owns 757,358 shares of Esperion Therapeutics, Inc. (ESPR), valued at approximately $2.39 M.

As of the Q2 2026 filing, Esperion Therapeutics, Inc. (ESPR) represents approximately 0.03% of George Soros's publicly disclosed stock portfolio, making it one of their key holdings.

George Soros's peak holding in Esperion Therapeutics, Inc. (ESPR) was 757,358 shares, as reported at the end of Q2 2026.